GB201619648D0 - Novel antibodies and uses thereof - Google Patents

Novel antibodies and uses thereof

Info

Publication number
GB201619648D0
GB201619648D0 GBGB1619648.7A GB201619648A GB201619648D0 GB 201619648 D0 GB201619648 D0 GB 201619648D0 GB 201619648 A GB201619648 A GB 201619648A GB 201619648 D0 GB201619648 D0 GB 201619648D0
Authority
GB
United Kingdom
Prior art keywords
novel antibodies
antibodies
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1619648.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alligator Bioscience AB
Original Assignee
Alligator Bioscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alligator Bioscience AB filed Critical Alligator Bioscience AB
Priority to GBGB1619648.7A priority Critical patent/GB201619648D0/en
Publication of GB201619648D0 publication Critical patent/GB201619648D0/en
Priority to NZ754051A priority patent/NZ754051A/en
Priority to AU2017360094A priority patent/AU2017360094B2/en
Priority to BR112019010265-5A priority patent/BR112019010265A2/pt
Priority to RU2019116624A priority patent/RU2019116624A/ru
Priority to MX2019005911A priority patent/MX2019005911A/es
Priority to KR1020197015905A priority patent/KR102679632B1/ko
Priority to IL266738A priority patent/IL266738B2/en
Priority to US16/461,544 priority patent/US11535678B2/en
Priority to CA3044339A priority patent/CA3044339A1/en
Priority to EP17811475.7A priority patent/EP3541844A2/en
Priority to CN201780071444.6A priority patent/CN109963873B/zh
Priority to JP2019527232A priority patent/JP7068303B2/ja
Priority to PCT/EP2017/079930 priority patent/WO2018091740A2/en
Priority to US16/514,374 priority patent/US10689454B2/en
Priority to US18/054,373 priority patent/US12509526B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1619648.7A 2016-11-21 2016-11-21 Novel antibodies and uses thereof Ceased GB201619648D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB1619648.7A GB201619648D0 (en) 2016-11-21 2016-11-21 Novel antibodies and uses thereof
PCT/EP2017/079930 WO2018091740A2 (en) 2016-11-21 2017-11-21 Novel antibodies and uses thereof
KR1020197015905A KR102679632B1 (ko) 2016-11-21 2017-11-21 신규한 항_cd137 항체 및 이의 용도
US16/461,544 US11535678B2 (en) 2016-11-21 2017-11-21 Anti-CD137 antibodies and uses thereof
BR112019010265-5A BR112019010265A2 (pt) 2016-11-21 2017-11-21 anticorpos anti_cd137 inovadores e usos dos mesmos
RU2019116624A RU2019116624A (ru) 2016-11-21 2017-11-21 Новые анти_cd137 антитела и их применение
MX2019005911A MX2019005911A (es) 2016-11-21 2017-11-21 Anticuerpos anti_cd137 novedosos y usos de estos.
NZ754051A NZ754051A (en) 2016-11-21 2017-11-21 Novel antibodies and uses thereof
IL266738A IL266738B2 (en) 2016-11-21 2017-11-21 Antibodies for Domain 2 of Human CD137 and Uses Thereof in Treatment of Cancer
AU2017360094A AU2017360094B2 (en) 2016-11-21 2017-11-21 Novel anti_CD137 antibodies and uses thereof
CA3044339A CA3044339A1 (en) 2016-11-21 2017-11-21 Anti-cd137 antibodies and uses thereof
EP17811475.7A EP3541844A2 (en) 2016-11-21 2017-11-21 Novel anti_cd137 antibodies and uses thereof
CN201780071444.6A CN109963873B (zh) 2016-11-21 2017-11-21 新颖抗cd137抗体和其用途
JP2019527232A JP7068303B2 (ja) 2016-11-21 2017-11-21 新規抗ｃｄ１３７抗体およびその使用
US16/514,374 US10689454B2 (en) 2016-11-21 2019-07-17 Anti-CD137 antibodies and uses thereof
US18/054,373 US12509526B2 (en) 2016-11-21 2022-11-10 Anti-CD137 antibodies and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1619648.7A GB201619648D0 (en) 2016-11-21 2016-11-21 Novel antibodies and uses thereof

Publications (1)

Publication Number Publication Date
GB201619648D0 true GB201619648D0 (en) 2017-01-04

Family

ID=57993708

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1619648.7A Ceased GB201619648D0 (en) 2016-11-21 2016-11-21 Novel antibodies and uses thereof

Country Status (14)

Country Link
US (3) US11535678B2 (enExample)
EP (1) EP3541844A2 (enExample)
JP (1) JP7068303B2 (enExample)
KR (1) KR102679632B1 (enExample)
CN (1) CN109963873B (enExample)
AU (1) AU2017360094B2 (enExample)
BR (1) BR112019010265A2 (enExample)
CA (1) CA3044339A1 (enExample)
GB (1) GB201619648D0 (enExample)
IL (1) IL266738B2 (enExample)
MX (1) MX2019005911A (enExample)
NZ (1) NZ754051A (enExample)
RU (1) RU2019116624A (enExample)
WO (1) WO2018091740A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112210010A (zh) * 2017-01-06 2021-01-12 优特力克斯有限公司 抗-人4-1bb抗体及其应用

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201831513A (zh) 2016-06-20 2018-09-01 Ｆ星貝塔有限公司 結合物件(一)
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
PE20200839A1 (es) 2017-08-01 2020-08-13 Lilly Co Eli Anticuerpos anti-cd137
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
CN112020517B (zh) 2018-03-23 2024-10-29 伊莱利利公司 用于与抗pd-l1抗体组合的抗cd137抗体
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811408D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
MX2021000399A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a cd137 y ox40.
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
US12344672B2 (en) 2018-07-12 2025-07-01 Invox Pharma Limited Antibody molecules that bind PD-L1 and CD137
JP7598312B2 (ja) 2018-07-23 2024-12-11 ハイデルベルク ファーマ リサーチ ゲーエムベーハー 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
KR102697702B1 (ko) 2018-08-10 2024-08-22 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
JP7387743B2 (ja) * 2018-09-12 2023-11-28 ユーカー（ベンジン） バイオファーマ カンパニー，リミテッド 抗ｔｎｆｒｓｆ９抗体及びその使用
CN120098128A (zh) * 2019-01-02 2025-06-06 Qlsf生物治疗药物公司 Cd137激动剂抗体及其用途
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
CN118791614A (zh) 2019-06-26 2024-10-18 圆祥生技股份有限公司 T细胞活化抗体
JP7432716B2 (ja) * 2019-11-13 2024-02-16 合肥瀚科邁博生物技術有限公司 ヒト４－１ｂｂに結合可能な分子及びその応用
US11396647B2 (en) 2020-01-07 2022-07-26 Board Of Regents, The University Of Texas System Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
EP4096789A4 (en) 2020-01-29 2023-10-11 Board of Regents, The University of Texas System USE OF POZIOTINIB TO TREAT CANCER WITH NRG1 FUSIONS
CN115362270A (zh) 2020-01-29 2022-11-18 得克萨斯州大学系统董事会 Egfr/her2酪氨酸激酶抑制剂和/或her2/her3抗体在具有nrg1融合的癌症的治疗中的用途
BR112022016491A2 (pt) * 2020-02-28 2022-10-11 Shanghai Henlius Biotech Inc Construto anti-cd137 e usos do mesmo
EP4153316A1 (en) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Binding molecules for the treatment of cancer
CN113842456B (zh) * 2020-06-28 2022-07-26 上海齐鲁制药研究中心有限公司 一种抗人4-1bb的单克隆抗体制剂及其用途
JP2023531042A (ja) * 2020-06-30 2023-07-20 諾納生物（蘇州）有限公司 ４－１ｂｂ結合タンパク質及びその用途
JP7744991B2 (ja) * 2021-01-08 2025-09-26 北京韓美薬品有限公司 ４－１ｂｂと特異的に結合する抗体及びその抗原結合フラグメント
US20240287199A1 (en) 2021-06-18 2024-08-29 Alligator Bioscience Ab Novel combination therapies and uses thereof
WO2023056361A1 (en) 2021-09-29 2023-04-06 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof
GB2629959A (en) * 2021-12-29 2024-11-13 Curateq Biologics Private Ltd C1Q binding assay
GB202210965D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202210957D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
JP2025531938A (ja) * 2022-09-22 2025-09-25 アブリンク バイオテック カンパニー リミテッド 抗４－１ｂｂナノボディ、その製造及び使用
CN116041517B (zh) * 2022-12-19 2025-02-25 首都医科大学附属北京胸科医院 一种抗人cd137抗体及其应用
CN116162162B (zh) * 2022-12-19 2025-05-27 首都医科大学附属北京胸科医院 一种大鼠抗小鼠cd137抗体或其功能性片段、工具抗体及其应用
CN116271009A (zh) * 2023-01-13 2023-06-23 深圳市乐土生物医药有限公司 含有CpG佐剂和4-1BB抗体的药物组合物及其用途
CN121666232A (zh) 2023-05-31 2026-03-13 开普斯坦治疗公司 脂质纳米颗粒制剂和组合物
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
AR046094A1 (es) * 2003-10-10 2005-11-23 Bristol Myers Squibb Co Anticuerpos completamente humanos contra 4-1bb humano
TWI423814B (zh) 2006-09-01 2014-01-21 Genticel 用於引發特異性細胞毒性ｔ淋巴細胞（ｃｔｌ）反應之組成物，包含一淋巴去除性化合物以及一含有抗原序列且以專業化抗原呈現細胞為標靶之分子
US20170247455A1 (en) * 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
TW201632559A (zh) * 2015-02-22 2016-09-16 索倫多醫療公司 結合ｃｄ１３７之抗體治療劑
US11008396B2 (en) 2015-05-21 2021-05-18 Alligator Bioscience Ab Polypeptides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112210010A (zh) * 2017-01-06 2021-01-12 优特力克斯有限公司 抗-人4-1bb抗体及其应用
CN112210010B (zh) * 2017-01-06 2023-12-05 优特力克斯有限公司 抗-人4-1bb抗体及其应用

Also Published As

Publication number Publication date
EP3541844A2 (en) 2019-09-25
IL266738A (en) 2019-07-31
BR112019010265A2 (pt) 2019-09-17
US12509526B2 (en) 2025-12-30
AU2017360094B2 (en) 2024-12-12
US10689454B2 (en) 2020-06-23
IL266738B1 (en) 2024-02-01
RU2019116624A (ru) 2020-12-21
AU2017360094A1 (en) 2019-06-20
CN109963873A (zh) 2019-07-02
NZ754051A (en) 2023-05-26
KR102679632B1 (ko) 2024-06-28
IL266738B2 (en) 2024-06-01
MX2019005911A (es) 2019-07-08
RU2019116624A3 (enExample) 2021-01-29
US20190352411A1 (en) 2019-11-21
KR20190086691A (ko) 2019-07-23
JP2020501531A (ja) 2020-01-23
CA3044339A1 (en) 2018-05-24
WO2018091740A3 (en) 2018-06-28
US20190352414A1 (en) 2019-11-21
US20230295325A1 (en) 2023-09-21
JP7068303B2 (ja) 2022-05-16
WO2018091740A2 (en) 2018-05-24
CN109963873B (zh) 2023-12-26
US11535678B2 (en) 2022-12-27

Similar Documents

Publication Publication Date Title
IL312910B1 (en) Anti-galectin-9 antibodies and their uses
IL283321A (en) Antibodies against muc16 and their uses
IL266738A (en) Novel antibodies and their uses
ZA202101318B (en) Anti-phf-tau antibodies and uses thereof
IL271477A (en) Anti-cd166 antibodies and their uses
IL267942B (en) Anti-cd73 antibodies and uses thereof
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
IL258284A (en) Anti-Lag 3 antibodies and their uses
SG11201808632YA (en) Anti-pacap antibodies and uses thereof
IL257263A (en) Antibodies against angptl8 and their use
ZA201901935B (en) Anti-il-33 antibodies and uses thereof
IL269134A (en) Antibodies against PAR2 and their use
IL254954B (en) Anti-pacap antibodies and their uses
IL273157A (en) Antibodies specific to AXL and their uses
IL272476A (en) Anti-Apelin antibodies and their uses
PT3292154T (pt) Anticorpos anti-her3 humano e seus usos
IL266082A (en) Anti-chikv antibodies and their use
IL266049A (en) Antibodies against o1 and their uses
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
IL264417A (en) Anti-o2 antibodies and their uses
GB201712032D0 (en) Antibodies and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)